ArticleBMC immunology2025
OmpA virulence factor, a promising conserved vaccine candidate against Acinetobacter baumannii, could trigger autoreactive immune responses in susceptible population.
Article in BMC immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mechanism of epitope mimicry could have implications for the safety of vaccine development. OmpA is one of the most promising antigens of Acinetobacter baumannii. This property convinced us to investigate OmpA's potential to trigger autoimmune responses. To this end, BLAST searches were performed using the OmpA sequence and its overlapping peptides to find identical peptides in the human proteome. These peptides were analyzed for their epitopic and HLA binding properties. The population coverage was then calculated for the peptides. OmpA showed high identity among numerous strains of A. baumannii and had no similar counterparts in the human proteome. Three OmpA peptides (TKNYDSKI, LSLARANS, and GQEAAAPA) shared identity and similarity with human proteins. Amongst, LSLARANS, which was found in Isthmin-1, the one with the highest potential to induce autoimmune responses was identified. LSLARANS was found in a B-cell positive assay of OmpA and acted as an HLA binder (such as HLA-A*03:01). Approximately 18% of the world's population were determined to be more susceptible to probable A. baumannii-post-infection autoimmune disease, which could be rooted in OmpA similarity. Mutation sensitivity analyses indicated that the TKNYDSKI peptide is sensitive to engineering and modification. Given these circumstances, these peptides should be avoided in vaccine design efforts to reduce the risk of autoimmune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.